Heidelberg Pharma Overview

  • Year Founded
  • 1997

Year Founded

  • Status
  • Public

  • Employees
  • 35

Employees

  • Stock Symbol
  • HPHA

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $2.27
  • (As of Thursday Closing)

Heidelberg Pharma General Information

Description

Heidelberg Pharma AG is a biopharmaceutical company developing oncology treatments through antibody drug conjugates (ADCs), which combine antibody specificity with toxin potency to selectively target and kill cancer cells. The Company researches, develops, and produces these ADCs, and has built an ADC toolbox using various antibodies and payloads to address multiple cancers and overcome tumor resistance. Its activities focus on its proprietary ATAC technology based on Amanitin, the toxin of the death cap mushroom, leveraging its biological mechanism as a novel cancer therapy. The ATAC platform is used to develop proprietary ADC candidates and is also applied in collaborations with third parties.

Contact Information

Formerly Known As
Wilex
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Gregor-Mendel-Stresse 22
  • 68526 Ladenburg
  • Germany
+49 06203
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
ETR
Vertical(s)
Corporate Office
  • Gregor-Mendel-Stresse 22
  • 68526 Ladenburg
  • Germany
+49 06203

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Heidelberg Pharma Stock Performance

As of 19-Nov-2026, Heidelberg Pharma’s stock price is $2.27. Its current market cap is $106M with 46.8M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.27 $2.26 $2.20 - $3.89 $106M 46.8M 3.85K -$0.76

Heidelberg Pharma Financials Summary

As of 31-Aug-2026, Heidelberg Pharma has a trailing 12-month revenue of $10.8M.

In Thousands,
USD
TTM 31-Aug-2026 FY 2025 30-Nov-2025 FY 2024 30-Nov-2024 FY 2023 30-Nov-2023
EV 106,703 131,538 79,675 91,842
Revenue 10,843 1,628 7,438 10,640
EBITDA (30,703) (43,888) (21,495) (21,941)
Net Income (34,796) (47,239) (21,047) (21,958)
Total Assets 49,621 44,227 64,236 77,185
Total Debt 346 133 174 6,398
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Heidelberg Pharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Heidelberg Pharma‘s full profile, request access.

Request a free trial

Heidelberg Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Heidelberg Pharma AG is a biopharmaceutical company developing oncology treatments through antibody drug conjugates (ADC
Pharmaceuticals
Ladenburg, Germany
35 As of 2026

Somerville, MA
 

Mannheim, Germany
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Heidelberg Pharma Competitors (2)

One of Heidelberg Pharma’s 2 competitors is Genetix Biotherapeutics, a Private Equity-Backed company based in Somerville, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Genetix Biotherapeutics Private Equity-Backed Somerville, MA
Affimed Formerly VC-backed Mannheim, Germany
You’re viewing 2 of 2 competitors. Get the full list »

Heidelberg Pharma Patents

Heidelberg Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2014220705-A1 Caix stratification based cancer treatment Active 22-Feb-2013
AU-2014220705-B2 Caix stratification based cancer treatment Active 22-Feb-2013
AU-2014220705-C1 Caix stratification based cancer treatment Active 22-Feb-2013
CA-2901531-A1 Caix stratification based cancer treatment Active 22-Feb-2013
CA-2901531-C Caix stratification based cancer treatment Active 22-Feb-2013 G01N33/57525
To view Heidelberg Pharma’s complete patent history, request access »

Heidelberg Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Heidelberg Pharma Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Heidelberg Pharma‘s full profile, request access.

Request a free trial

Heidelberg Pharma Acquisitions (2)

Heidelberg Pharma’s most recent deal was a Merger/Acquisition with Heidelberg Pharma (Acquired by Wilex) for . The deal was made on 15-Dec-2010.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Heidelberg Pharma (Acquired by Wilex) 15-Dec-2010 Merger/Acquisition Pharmaceuticals
Siemens Healthcare Diagnostics (Oncogene Science Business) 18-Nov-2010 Merger/Acquisition Pharmaceuticals
To view Heidelberg Pharma’s complete acquisitions history, request access »

Heidelberg Pharma ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Heidelberg Pharma’s complete esg history, request access »

Heidelberg Pharma FAQs

  • When was Heidelberg Pharma founded?

    Heidelberg Pharma was founded in 1997.

  • Where is Heidelberg Pharma headquartered?

    Heidelberg Pharma is headquartered in Ladenburg, Germany.

  • What is the size of Heidelberg Pharma?

    Heidelberg Pharma has 35 total employees.

  • What industry is Heidelberg Pharma in?

    Heidelberg Pharma’s primary industry is Pharmaceuticals.

  • Is Heidelberg Pharma a private or public company?

    Heidelberg Pharma is a Public company.

  • What is Heidelberg Pharma’s stock symbol?

    The ticker symbol for Heidelberg Pharma is HPHA.

  • What is the current stock price of Heidelberg Pharma?

    As of 19-Nov-2026 the stock price of Heidelberg Pharma is $2.27.

  • What is the current market cap of Heidelberg Pharma?

    The current market capitalization of Heidelberg Pharma is $106M.

  • What is Heidelberg Pharma’s current revenue?

    The trailing twelve month revenue for Heidelberg Pharma is $10.8M.

  • Who are Heidelberg Pharma’s competitors?

    Genetix Biotherapeutics and Affimed are competitors of Heidelberg Pharma.

  • What is Heidelberg Pharma’s annual earnings per share (EPS)?

    Heidelberg Pharma’s EPS for 12 months was -$0.76.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process